arrow
K

Katherine Esposito

university of campania luigi vanvitelli
H指数:95
被引数:3.8万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Optimizing the use of the Omnipod 5 system in adults with type 1 diabetes: an Italian expert Delphi consensus

优化Omnipod 5系统在1型糖尿病成人中的使用:一项意大利专家德尔菲共识

2026-09-220
PRE
Glucagon-like peptide-1 receptor agonists and major limb events in adults with type 2 diabetes and peripheral artery disease: a systematic review and meta-analysis of RCTs and cohort studies

胰高血糖素样肽-1受体激动剂与2型糖尿病合并外周动脉疾病成人主要肢体事件:一项对随机对照试验和队列研究的系统评价和荟萃分析

2026-07-060
OAAI
Late-onset hypogonadism and lower limb vascular complications in men with type 2 diabetes: an observational study in a tertiary care centre

2型糖尿病男性患者中迟发性性腺功能减退与下肢血管并发症的关系:一项在三级护理中心开展的临床观察研究

2026-06-260
OAAI
Exploring Insulin Resistance in Adults With Type 1 Diabetes: The Role of the Estimated Glucose Disposal Rate and the Triglyceride Glucose Index

探索1型糖尿病成人中的胰岛素抵抗:估计葡萄糖处置率及甘油三酯葡萄糖指数的作用

2025-10-200
PRE
The Glycemia Risk Index (GRI) as a Biomarker for Subclinical Endothelial Dysfunction in Type 1 Diabetes: A Cross-Sectional Study

糖化血红蛋白风险指数(GRI)作为1型糖尿病亚临床内皮功能障碍的生物标志物:一项横断面研究

2025-09-210
OAAI
BEYOND 4 years: simplification of complex insulin regimens with a fixed-ratio combination of basal insulin plus a GLP-1 receptor agonist or basal insulin plus an SGLT-2 inhibitor

BEYOND 4年:通过基础胰岛素与GLP-1受体激动剂或基础胰岛素与SGLT-2抑制剂固定比例联合用药简化复杂胰岛素方案

2025-08-280
PRE
Real-world safety comparison of liraglutide and semaglutide in weight management: Insights from European pharmacovigilance data

利拉鲁肽和司美格鲁肽在体重管理中的真实世界安全性比较:来自欧洲药物警戒数据的见解

2025-07-250
OA
Association of semaglutide with less limb events in people with type 2 diabetes and peripheral artery disease or foot ulcers: An observational study comparing matched cohorts

司美格鲁肽与2型糖尿病合并外周动脉疾病或足部溃疡患者肢体事件减少的关联:一项比较匹配队列的观察性研究

2025-07-070
PRE